;The Human Cancer Virology (VR) program is advancing understanding, prevention, and treatment of virus linked cancers and other cancers through fundamental and translational studies that encompass five of the seven well-established human tumor viruses. Program members are defining the mechanisms by which human tumor viruses replicate, maintain chronic infection, and promote tumor induction and maintenance;determining the progressive, genome-wide molecular changes in the development of virus-associated tumors;identifying viral and cellular biomarkers for improved tumor diagnosis, prognosis and treatment selection;and using their results to develop new approaches to prevent and treat tumor virus infection and oncogenesis. Program members'efforts have already changed UW-Madison clinical practices for hepatitis C virus treatment, are moving forward in testing new treatment approaches for papillomavirus-induced head/neck and cervical cancer, and have established strong foundations for similarly novel control strategies for cancers induced by Epstein-Barr virus and other viruses. To achieve their goals, program members collaborate extensively intra- and inter-programmatically, and integrate novel, synergistic approaches using cell culture, mouse models based on transgenes and patient explants, and large collections of relevant human tumor samples. The twelve program members include three practicing physician-scientists (two M.D.s and one M.D./Ph.D.) and nine Ph.D.s who collectively comprise a highly productive, interactive, diverse, and critical mass of expertise across the full spectrum of tumor virology from molecular biology to clinical studies. They represent six departments (Oncology, Medical Microbiology and Immunology, Medicine, Molecular Virology, Plant Pathology) in four Schools (School of Medicine and Public Health, Graduate School, College of Engineering, College of Agriculture and Life Sciences), plus two private biomedical research institutes (Howard Hughes Medical Institute and Morgridge Institute for Research). They have $3.8M/yr funding from NCI and $2.7M in other peer-reviewed funding. From 2007-2011 they had 133 cancer-relevant publications, which were overall 6% intra-programmatic and 15% inter-programmatic. For 2011, intra-programmatic publications advanced to 12% and inter-programmatic publications to 25%. This increase in collaborative publications reflects a steadily increasing number of joint projects and grants within and beyond the program.

Public Health Relevance

;Specific human tumor viruses have been causally associated with at least 15-20% of all human cancers. The Human Cancer Virology program advances the understanding, prevention, and treatment of virus-linked cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014520-40
Application #
8762763
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
40
Fiscal Year
2014
Total Cost
$269,656
Indirect Cost
$59,444
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Lee, Cindy S; Sickles, Edward A; Burnside, Elizabeth S (2018) Data-Driven Mammography Screening Practices-Reply. JAMA Oncol 4:588-589
Djavadian, Reza; Hayes, Mitchell; Johannsen, Eric (2018) CAGE-seq analysis of Epstein-Barr virus lytic gene transcription: 3 kinetic classes from 2 mechanisms. PLoS Pathog 14:e1007114
Engle, Jeff A; Traynor, Anne M; Campbell, Toby C et al. (2018) Assessment of adherence and relative dose intensity with oral chemotherapy in oncology clinical trials at an academic medical center. J Oncol Pharm Pract 24:348-353
Cummings, Nicole E; Williams, Elizabeth M; Kasza, Ildiko et al. (2018) Restoration of metabolic health by decreased consumption of branched-chain amino acids. J Physiol 596:623-645
McDaniel, Nellie K; Cummings, Christopher T; Iida, Mari et al. (2018) MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents. Mol Cancer Ther 17:2297-2308
Tucholka, J L; Jacobson, N; Steffens, N M et al. (2018) Breast cancer survivor's perspectives on the role different providers play in follow-up care. Support Care Cancer 26:2015-2022
Mukaddim, Rashid Al; Rodgers, Allison; Hacker, Timothy A et al. (2018) Real-Time in Vivo Photoacoustic Imaging in the Assessment of Myocardial Dynamics in Murine Model of Myocardial Ischemia. Ultrasound Med Biol 44:2155-2164
Eslani, Medi; Putra, Ilham; Shen, Xiang et al. (2018) Cornea-Derived Mesenchymal Stromal Cells Therapeutically Modulate Macrophage Immunophenotype and Angiogenic Function. Stem Cells 36:775-784
Tanratana, Pansakorn; Ellery, Paul; Westmark, Pamela et al. (2018) Elevated Plasma Factor IXa Activity in Premenopausal Women on Hormonal Contraception. Arterioscler Thromb Vasc Biol 38:266-274
Mora-Pinzon, Maria C; Chrischilles, Elizabeth A; Greenlee, Robert T et al. (2018) Variation in coordination of care reported by breast cancer patients according to health literacy. Support Care Cancer :

Showing the most recent 10 out of 1528 publications